Journals / Türk Kardiyoloji Derneği Arşivi / 2006 / Cilt: 34 - Sayı: 4

Do we pay proper attention to triglyceride levels in coronary artery disease?

Koroner arter hastalığında trigliserid düzeylerine gereken önemi veriyor muyuz?

Pages
218–222
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to the Adult Treatment Panel III (ATP III), triglyceride levels were normal (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Epidemiological studies have demonstrated that elevated triglyceride levels increase the risk for coronary artery disease (CAD).
📊
Key Findings & Data:Study design: The study consisted of 100 consecutive patients (79 males, 21 females; mean age 58±10 years) who were admitted to the cardiology department of a university hospital with angina pectoris and were found to have CAD by elective coronary angiography.
💡
Conclusion & Impact:According to the Adult Treatment Panel III (ATP III), triglyceride levels were normal (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: Epidemiological studies have demonstrated that elevated triglyceride levels increase the risk for coronary artery disease (CAD). This study sought to evaluate the approach to triglyceride levels in patients with CAD in the cardiology department of a tertiary medical center. Study design: The study consisted of 100 consecutive patients (79 males, 21 females; mean age 58±10 years) who were admitted to the cardiology department of a university hospital with angina pectoris and were found to have CAD by elective coronary angiography. Data were obtained from hospital records. Lipid profiles of the patients and management strategies were assessed. Results: Hyperlipidemia was detected in 66%. The mean total cholesterol, triglyceride, high- and low-density lipoprotein cholesterol levels were 203±44 mg/dl, 195±106 mg/dl, 43±11 mg/dl, and 124±38 mg/dl, respectively. On admission, none of the patients were receiving fibrates, and 31% were on statin treatment, which increased to 65% on discharge. In 10 patients, triglyceride levels were not determined at all. According to the Adult Treatment Panel III (ATP III), triglyceride levels were normal (

Özet

Amaç: Epidemiyolojik çalışmalar yüksek trigliserid düzeylerinin koroner arter hastalığı (KAH) riskini artırdığını göstermiştir. Bu çalışmada, bir üçüncü basamak sağlık merkezinin, koroner arter hastalarında trigliserid düzeylerine yaklaşımı değerlendirildi. Çalışma planı: Çalışmaya, bir üniversite hastanesi kardiyoloji kliniğine son bir ay içinde angina pektoris yakınmasıyla başvuran ve elektif koroner anjiyografi amacıyla yatırılarak KAH saptanan ardışık 100 hasta (79 erkek, 21 kadın; ort. yaş 58±10) alındı. Çalışma verileri olguların hastane dosya kayıtlarından elde edildi. Hastaların lipid profilleri ve uygulanan tedaviler incelendi. Bulgular: Hastaların %66’sı hiperlipidemikti. Ortalama lipid düzeyleri şu şekildeydi: Total kolesterol 203±44 mg/dl; trigliserid 195±106 mg/dl; yüksek yoğunluklu lipoprotein 43±11 mg/dl, düşük yoğunluklu lipoprotein 124±38 mg/dl. Olguların %31’i yatışta statin kullanıyordu ve taburcu olurken %65’ine statin önerilmişti. Hiçbir hasta yatışta fibrat türevi kullanmıyordu. On hastada trigliserid düzeyine hiç bakılmamıştı. Trigliserid düzeyinin ölçüldüğü hastaların sadece 29'unda (%32.2) trigliserid düzeyi ATP III kılavuzuna göre normal sınırlardaydı (

🔖

Cite This Article

HASDEMİR, C., CAN, L., YAVUZGİL, O., GÜRGÜN, C., SOYDAN, İ., ILDIZLI, M., OLUKMAN, M., KAYIKÇIOĞLU, M., KÜLTÜRSAY, H. (2022). Do we pay proper attention to triglyceride levels in coronary artery disease?. Türk Kardiyoloji Derneği Arşivi, Cilt: 34 - Sayı: 4, 218–222. https://ajindex.com/articles/633678

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-84
  2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
  3. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 1998;82:22Q-25Q
  4. Ravi GR, Pradeepa R, Mohan V. Hypertriglyceridemia and coronary artery disease-an update. Indian Heart J 2004;56:21-6
  5. UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK Consensus. Curr Med Res Opin 2004;20:241-7
  6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
  7. Okopien B, Cwalina L, Haberka M, Kowalski J, Zielinski M, Szwed Z, et al. Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia. Pol Merkuriusz Lek 2002;13:465-9. [Abstract] 8. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347:849-53
  8. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-10
  9. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
  10. Davidson MH. Management of dyslipidemia in patients with complicated metabolic syndrome. Am J Cardiol 2005;96:22E-25E
  11. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001;156:1-10
  12. Onat A. Lipids, lipoproteins and apolipoproteins among Turks, and impact on coronary heart disease. Anadolu Kardiyol Derg 2004;4:236-45
  13. Barbagallo CM, Averna MR, Citarrella R, Rizzo M, Amato M, Noto D, et al. Transient chylomicronemia preceding the onset of insulin-dependent diabetes in a young girl with no humoral markers of islet autoimmunity. Eur J Endocrinol 2004;150:831-6
  14. Ayvaz G, Balos Toruner F, Karakoc A, Yetkin I, Cak